COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy.
J Nephrol
; 35(1): 317-321, 2022 Jan.
Article
in English
| MEDLINE | ID: covidwho-1370413
ABSTRACT
There is a high incidence of acute kidney injury with COVID-19 infections. The etiologies of acute kidney injury could be ischemic acute tubular necrosis or a complex process of complement activation leading to thrombotic microangiopathy. We present a case of 32-year-old Hispanic male with a history of heart transplant, admitted with COVID-19 and atypical hemolytic uremic syndrome, which was successfully treated with Eculizumab.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Atypical Hemolytic Uremic Syndrome
/
COVID-19
Type of study:
Case report
/
Diagnostic study
/
Etiology study
/
Observational study
/
Prognostic study
Limits:
Adult
/
Humans
/
Male
Language:
English
Journal:
J Nephrol
Journal subject:
Nephrology
Year:
2022
Document Type:
Article
Affiliation country:
S40620-021-01125-8
Similar
MEDLINE
...
LILACS
LIS